Effective HCV Treatment Prolongs Survival

The life expectancy of patients with chronic HCV infection and cirrhosis who achieved sustained virologic response was comparable to that of the general population.

A key question for patients and providers regarding treatment for chronic hepatitis C virus (HCV) infection is the clinical benefit of therapy. To explore this issue, investigators further analyzed the survival of a previously studied population of patients with chronic HCV monoinfection and either bridging fibrosis or cirrhosis. In this new analysis, they compared the life expectancy of participants who did — or did not — achieve a sustained virologic response (SVR) with that of the general population in the Netherlands.

Data were analyzed for 530 patients who had been treated with interferon-containing regimens at any of five hepatology centers in Europe and Canada between 1990 and 2003. Of the 192 patients who attained SVR, 13 died. The 1…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Effective HCV Treatment Prolongs Survival

Topics

Reviewing Author